INCB123667
Sponsors
Incyte Corporation
Conditions
Healthy ParticipantsHepatic InsufficiencyLiver DiseasesOvarian CancerRenal Impairment
Phase 1
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
CompletedNCT06909162
Start: 2025-05-05End: 2026-05-17Updated: 2026-06-15
Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants
CompletedNCT07218744
Start: 2025-11-13End: 2025-12-10Updated: 2026-01-07
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
RecruitingNCT07559474
Start: 2026-05-27End: 2027-04-13Target: 16Updated: 2026-06-16
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
RecruitingNCT07559396
Start: 2026-05-29End: 2027-01-04Target: 16Updated: 2026-06-16
Phase 2
Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RecruitingNCT07214779
Start: 2025-12-09End: 2029-05-14Target: 466Updated: 2026-08-06
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
Not yet recruitingNCT07797283
Start: 2026-12-01End: 2034-05-01Target: 590Updated: 2026-09-09